REVERSIBLE NONOLIGURIC ACUTE-RENAL-FAILURE ASSOCIATED WITH ZOMEPIRAC THERAPY

  • 1 January 1982
    • journal article
    • research article
    • Vol. 57  (6) , 351-354
Abstract
Zomepirac sodium (Zomax) is a nonsteroidal antiinflammatory agent with analgesic properties which was recently released for clinical use. A case of nonoliguric acute renal failure associated with zomepirac sodium therapy is reported. This acute renal failure improved upon cessation of zomepirac treatment. Renal biopsy disclosed the presence of a tubulointerstitial nephritis, which was thought to have been responsible for the acute renal failure in this patient. Clinicians should be aware of the potential nephrotoxicity of zomepirac sodium and use caution in its administration, especially in patients with compromised intravascular volume status, hypertension or preexistent chronic renal disease.